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received the administration of placebo or TJ-14 for 2 weeks 
at the start of the next course of chemotherapy. Patients 
were assessed three times per week for safety and for COM 
incidence and its severity using the WHO grading.
Results Ninety eligible patients (TJ-14; 43, placebo; 
47) per protocol set analysis were included in the anal-
ysis after the key-opening. Although the incidence of 
grade ≧2 oral mucositis was lower for patients treated 
with TJ-14 compared to those treated with placebo, 
there was no significant difference (48.8 vs. 57.4 %; 
p = 0.41). The median duration of grade ≧2 mucositis 
was 5.5 versus 10.5 days (p = 0.018). No difference in 
other treatment toxicity was observed between the two 
groups, and patients exhibited high compliance in dosing 
administration.
Conclusion The present study results did not meet the pri-
mary endpoint. However, TJ-14 demonstrated a significant 
effect in the treatment of grade ≧2 mucositis in patients 
with colorectal cancer compared to the placebo.
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Introduction
Oral mucositis is a common complication of systemic high-
dose chemotherapy as well as radiotherapy for cancer [1, 
2]. Oral mucositis is associated with higher risk of infec-
tion, pain, chemotherapy dose reduction, and infection-
related death. Severe mucositis impairs oral and esophageal 
functions and seriously affects nutrition and quality of life 
of the patients. Consequently, oral mucositis can result in 
therapeutic noncompliance or become a dose-limiting tox-
icity that requires treatment modifications or interruption 
Abstract 
Purpose Hangeshashinto (TJ-14, a Kampo medicine), 
which reduces the level of prostaglandin E2 and affects the 
cyclooxygenase activity, alleviates chemotherapy-induced 
oral mucositis (COM). We conducted a double-blind, pla-
cebo-controlled, randomized comparative trial to investi-
gate whether TJ-14 prevents and controls COM in patients 
with colorectal cancer.
Methods Ninety-three patients with colorectal cancer 
who developed moderate-to-severe COM (WHO grade ≧1) 
during any cycle of chemotherapy using FOLFOX, FOL-
FIRI, and/or XELOX treatment were randomly assigned to 
receive either TJ-14 (n = 46) or placebo (n = 47). Patients 
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and eventually affect the outcome of cancer therapy. Sev-
eral reviews and clinical practice guidelines have confirmed 
the need for increased emphasis on the management of 
mucositis [3–5].
Despite the attempts to reduce cancer chemotherapy-
related mucositis, there has been no standard efficacious 
prophylactic therapy. Treatment is mostly supportive, con-
sisting of good oral hygiene, mouthwashes, and analgesia 
[2].
Evidence from randomized trials suggests that the use of 
oral ice tips before chemotherapy improves oral mucositis 
by decreasing blood flow and decreases drug absorption [6–
8]. Other clinical trials attempting to evaluate various strat-
egies to prevent or reduce chemotherapy-induced mucosi-
tis, enrolled only small numbers of patients in their studies, 
and were thus inconclusive [9–13]. Only in two studies of 
large randomized double-blind, placebo-controlled trials 
were treatments reported to be effective against mucositis. 
One trial involved 326 women with breast cancer receiv-
ing an anthracycline regimen, and a new agent AES-14 was 
reported to significantly reduce the incidence of mucositis, 
although this result has not yet been reproduced or recon-
firmed [14]. The other study investigating the effect of 
human epidermal growth factor for mucositis in head and 
neck cancer patients, proved significant reduction in severe 
oral mucositis receiving radiotherapy and chemotherapy 
[15]. Despite those results, it is still unclear whether there 
is any definite evidence for the prevention and treatment of 
cancer chemotherapy-induced oral mucositis to date.
The mechanism of chemotherapy-induced mucositis has 
been investigated and a report speculated that the cycloox-
ygenase pathway mediates tissue injury and pain through 
upregulation of pain-evoking prostaglandin E2 and proin-
flammatory cytokines [16, 17]. TJ-14 (Hangeshashinto), a 
traditional Japanese herbal (Kampo) medicine, was shown 
to significantly decrease production of prostaglandin E2 
in human oral keratinocytes in hamsters. The gene expres-
sions of cyclooxygenase 2, cytosolic phospholipase A2, 
and prostaglandin E synthase were also down-regulated by 
exposure to TJ-14 [18]. A clinical study demonstrated that 
topical administration of TJ-14 significantly reduced grade 
3/4 mucositis in 13 out of 14 patients with oral mucositis, 
and TJ-14 was considered to have therapeutic effect on 
chemotherapy-induced oral mucositis via down regulation 
of proinflammatory prostaglandins in the cyclooxygenase 
pathway [19].
Given those biochemical and in vivo study findings, in 
the present study, the efficacy of TJ-14 for the prevention 
and/or treatment of chemotherapy-induced oral mucositis 
was investigated in a randomized double-blind, placebo-




A multi-institutional, double-blind, placebo-controlled 
randomized phase 2 trial was performed in patients 
receiving chemotherapy for advanced colorectal can-
cers in Japan. Patients who developed WHO grade ≧1 
oral mucositis during the first screening cycle of chemo-
therapy were eligible for randomization to the study. 
Eligible patients were centrally randomized to receive 
either TJ-14 or placebo during their next second cycle of 
chemotherapy. Patients were stratified by chemotherapy 
regimen before randomization in a 1:1 ratio. A matched 
placebo, specially made and prepared, was utilized to 
maintain blinding. The primary objective of this study 
was to determine the efficacy and safety of TJ-14 com-
pared to placebo when used to reduce the incidence of 
severe (WHO grade ≧3) oral mucositis associated with 
mucotoxic FOLFOX, FOLFIRI, or XELOX chemother-
apy for advanced colorectal cancer. Secondary objec-
tives were to determine the treatment effect of TJ-14 
compared to placebo on the duration of WHO grade 
≧2 oral mucositis, and the worst oral mucositis grade 
throughout the protocol therapy. Time to disappearance 
of oral mucositis was also compared between the two 
treatments.
Ethical considerations
The study data and informed consent were obtained in 
accordance with the Declaration of Helsinki and were 
approved by the Ethics Review Board of each participating 
institution.
Study drug
Both TJ-14 and placebo were administered at a dose of 
2.5 g X3 times per day for a total daily dose of 7.5 g. 
The placebo formulation matched the texture, flavor, and 
other characteristics of the active drug. Patients were 
advised to dissolve 2.5 g of TJ-14 or placebo in 50 ml 
of drinking water, divided it into twice or three times in 
an oral cavity. They rinsed their oral cavity with it three 
times daily. In principal, the patients were trained and 
validated by the physician at out patient’s clinic. Study 
drug treatment began on the first day of chemotherapy 
and continued for 14 days. Patients followed oral care 
instruction throughout the treatment before the next 
course of chemotherapy began. No other prophylactic 
mouthwashes or treatment for mucositis were allowed in 
this clinical trial.
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Study assessments
Signs and symptoms of oral mucositis were assessed by 
the investigator 3 times per week on nonconsecutive days 
during the screening cycle and during treatment cycle 1 
and 2 (on days 3, 5, 7, 9, 11, and 14) and additionally on 
days 16 and 18 of each cycle. The WHO oral mucositis 
scale was used to assess the severity of oral mucositis. Oral 
assessment continued for the first 3 weeks or until mucosi-
tis returned to grade 0. Additionally, patients themselves 
reported their ability to eat foods.
Safety was assessed throughout the study by physical 
examination, including inspection of oral tissues, hema-
tology and serum chemistry laboratory tests, and adverse 
event reporting. Any adverse event, whether or not related 
to the study drug, was reported with date and time of onset, 
severity, pattern, action taken, and outcome. If the adverse 
event had not resolved at the time the case report forms 
were collected, a follow-up report was provided at a later 
date. If no follow-up report was provided, the investigator 
had to give a justification. All adverse events were followed 
until they either resolved or the investigator determined 
that the event was no longer clinically significant. Tumor 
response to chemotherapy was also evaluated every month. 
RECIST ver. 1.1 criteria were used to assess the efficacy of 
chemotherapy to the target lesion.
Statistical analyses
Eligible patients were randomly assigned on a 1:1 ratio to 
receive either TJ-14 or placebo. After checking patient eli-
gibility, randomization was carried out centrally at the data 
center using minimization with the stratification factors, 
including chemotherapy regimen (adjuvant chemotherapy 
for resected tumor/chemotherapy for advanced and/or met-
astatic cancer), previous history for any type of stomatitis 
treatment (yes/no), age (<60/≧60), and institution.
The primary endpoint of this study was the incidence of 
persisting grade ≧2 oral mucositis for over 1 week, which 
was compared between the TJ-14 and placebo groups using 
the Chi-squared test.
Assuming that the incidence of oral mucositis of grade 
2 or greater was 10 % in the TJ-14 group and 35 % in the 
placebo group, 42 patients per group were required to com-
pare the two treatment groups using Chi-squared test with a 
two-sided α = 0.10 and a power of 80 %. Thus, to account 
for possible dropouts, a target sample size of 90 patients 
was required. The secondary endpoints included the dura-
tion of grade ≧2 oral mucositis, and the worst oral mucosi-
tis grade throughout the protocol therapy, and time to dis-
appearance of oral mucositis. The time-to-event data were 
analyzed using the Kaplan–Meier method and compared 
between the treatments groups using the log-rank test. All p 
values were two-sided. Statistical analyses were performed 




Of 707 patients in 19 participating institutions who were 
receiving 5-FU-based chemotherapies for colorectal can-
cers, 93 who developed WHO grade ≧1 oral mucositis 
during the screening cycle and provided informed con-
sent were randomized to either TJ-14 (n = 46) or placebo 
(n = 47) after the first treatment cycle. Among those, pro-
jected administration could not be started in three patients 
in the TJ-14 group and thus they were excluded from the 
study. Baseline demographics and disease characteris-
tics for the per protocol set (PPS) population are shown 
(Table 1). 55.5 % were men and 44.5 % were women; 
median age was 67 years (range 29–85 years). All patients 
had histologically confirmed adenocarcinoma of the colon 
(69.0 %) and rectum (31.0 %). Slight disparity in gender 
(p = 0.186) and performance status (p = 0.178) distribu-
tion was noticed between the two PPS randomized groups. 
Table 1  Patient characteristics of the TJ-14 and placebo groups
Treatment TJ-14 (n = 43) Placebo (n = 47) p value
Sex
 Male 27 (62.8 %) 23 (48.9 %) 0.186
 Female 16 (37.2 %) 24 (51.1 %)
Age
 Median 67.0 67.0 0.376
 Range 49.0–84.0 29.0–85.0
PS
 0 34 (79.1 %) 42 (89.4 %) 0.178
 1 9 (20.9 %) 5 (10.6 %)
Location
 Colon 29 (67.4 %) 33 (70.2 %) 0.777
 Rectum 14 (32.6 %) 14 (29.8 %)
Status
 Adjuvant 10 (23.3 %) 14 (29.8 %) 0.484
 Advanced 33 (76.7 %) 33 (70.2 %)
Oral care (patient)
 + 4 (9.3 %) 2 (4.3 %) 0.338
 − 39 (90.7 %) 45 (95.7 %)
Oral care (institution)
 + 11 (25.6 %) 10 (21.3 %) 0.630
 − 32 (74.4 %) 37 (78.7 %) 1
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The majority of patients received FOLFOX (40 %), FOL-
FIRI (30 %), or XELOX (7.8 %), and treatment groups 
were balanced for chemotherapy regimen (Table 2). No 
patient received radiation therapy before enrollment. No 
patient was enrolled in the study if there was any clinical 
evidence of another active oral mucosal disease at baseline. 
More than 90 % of the PPS patients completed the study, 
with little difference in the rate of discontinuation or post-
ponement during treatment with TJ-14 or placebo.
Incidence and severity of oral mucositis
During the test treatment cycle, the incidence of WHO 
grade ≧2 mucositis was lower for patients treated 
with TJ-14 compared to those treated with placebo 
(48.8 %(21/43) vs 57.4 %(27/47); relative risk, 0.85, 
95 % CI 0.57–1.26), which corresponds to a 15 % risk 
reduction with TJ-14. However, the difference was not sta-
tistical (p = 0.41) in terms of the effect of TJ-14 in reduc-
ing severity of mucositis.
Duration of grade ≧2 oral mucositis
The median duration of grade ≧2 oral mucositis was 
5.5 days in the TJ-14 group and 10.5 days in the placebo 
group (p = 0.018) (Fig. 1). Treatment with TJ-14 was asso-
ciated with a statistically significant reduction in the dura-
tion of severe grade ≧2 oral stomatitis compared to patients 
receiving placebo.
Safety
Hematological, blood biochemistry, and nonhematologi-
cal toxicities were analyzed. The most commonly reported 
treatment adverse events including nausea, anorexia, leuko-
penia, anemia, slight liver dysfunction, and diarrhea, all of 
which typically occur in cancer patients receiving cytotoxic 
chemotherapy (Tables 3, 4). The majorities of these events 
were mild to moderate in severity and considered unrelated 
to the study drug.
Discussion
Kampo medicine or Japanese/Chinese traditional herbal 
medicine has been used for the treatment of various dis-
eases for over 2000 years, mainly in many Asian countries. 
Although the beneficial effect of those Kampo medicines 
has long been taken for granted, and was widely utilized 
among Asian populations, two substantial factors have pre-
cluded their approval in the modern western world. One 
reason is that Kampo medicines are the mixture of several 
ingredients, and it was believed that combination of those 
ingredients could exert a synergistic effect. Since analysis 
of the efficacy of each ingredient is imperative in mod-
ern science, attempts to elucidate their mechanisms have 
not been fully successful to date. Another reason is that 
Table 2  Treatments for the TJ-14 and placebo groups
Hange (n = 43) Placebo (n = 47) p value
Chemotherapy at the time of registration
 FOLFOX 17 (39.5 %) 19 (40.4 %) 0.752
 FOLFIRI 11 (25.6 %) 16 (34.0 %)
 XELOX 4 (9.3 %) 3 (6.4 %)
 Others 11 (25.6 %) 9 (19.1 %)
Postponed protocol treatment
 + 3 (7.0 %) 4 (8.5 %) 0.786
 − 40 (93.0 %) 43 (91.5 %)
Postponed secondary treatment
 + 8 (19.0 %) 10 (21.7 %) 0.755
 − 34 (81.0 %) 36 (78.3 %)
Fig. 1  Duration of grade ≧2 
mucositis between the treatment 
groups
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the reports on the clinical effectiveness of those Kampo 
medicines used to be mostly anecdotal, and reliable well-
conducted clinical trials to elucidate the evidence of the 
efficacy have not been satisfactory. In recent years, Asian 
investigators have attempted to clarify the mechanism and 
clinical efficacy of the Kampo medicine. The anti-inflam-
matory effect of Inchinkoto (ICKT) in Wistar rats was 
proved to improve mortality by ischemic reperfusion of the 
liver, caused by extensive hepatectomy [20]; Daikenchuto 
(DKT) showed its effects in revitalizing bowel movement 
after laparotomy operations in 30 patients [21]. Also, the 
efficacy of Goshajinkigan (GJG) to alleviate neuropathy 
after oxaliplatin treatment for colon cancers was investi-
gated in a placebo-controlled randomized phase II trial, and 
promising results have recently been reported [22].
TJ-14, also one of the Kampo formulas in Japanese 
traditional herbal medicine, is the mixture of seven herbs 
including pinellia tuber, scutellaria root, glycyrrhiza, 
jujube, ginseng, processed ginger, and Coptis rhizome, 
which are registered in the Japanese Pharmacopoeia XV 
[23]. In clinical practice, TJ-14 has been used for acute 
or chronic diarrhea, acute gastroenteritis, and for chronic 
hypoperfusion of the gastrointestinal system [24, 25]. It is 
reported that TJ-14 is effective against diarrhea which is 
the side effect of chemotherapeutic agents for gastrointesti-
nal cancers [26]. Since TJ-14 contains baicalin, an inhibitor 
of β-glucuronidase, a randomized trial for advanced small 
cell lung cancer demonstrated the effect of TJ-14 in signifi-
cantly controlling grade ≧3 diarrhea caused by cisplatin/iri-
notecan treatment with a p value of 0.018 [27, 28]. Moreo-
ver, recently, TJ-14 has attracted attention not only for its 
effect on intestinal mucosa but also concerning its efficacy 
on oral mucositis. Promising results were published both in 
vivo [18] and in clinical studies with a topical application 
of TJ-14 at the ulcerated site of the oral cavity [19].
The present study was conducted to clarify the effect 
of TJ-14 in patients who developed grade ≧1 mucositis 
after the first course of chemotherapy for colorectal can-
cer. With the advent of prospectively randomized pla-
cebo–controlled clinical trial, results showing a significant 
Table 3  Hematological and 
biochemical toxicities observed 
during treatment
Grade ≧1 Grade ≧2
TJ-14 (n = 43) Placebo (n = 47) p value TJ-14 (n = 43) Placebo (n = 47) p value
Leukopenia 2 (4.7 %) 1 (2.1 %) 0.505 0 (0.0 %) 0 (0.0) %) 1.000
Neutropenia 1 (2.3 %) 1 (2.1 %) 0.949 0 (0.0 %) 1 (2.1 %) 0.336
Hb 23 (53.5 %) 20 (42.6 %) 0.300 0 (0.0 %) 2 (4.3 %) 0.171
PLT 9 (20.9 %) 10 (21.3 %) 0.968 0 (0.0 %) 0 (0.0) %) 1.000
T-Bill 0 (0.0 %) 2 (4.3 %) 0.171 0 (0.0 %) 0 (0.0) %) 1.000
AST 7 (16.3 %) 9 (19.1 %) 0.722 0 (0.0 %) 0 (0.0) %) 1.000
Hemorrhage 1 (2.3 %) 1 (2.1 %) 0.949 0 (0.0 %) 0 (0.0) %) 1.000
Table 4  Nonhematological toxicities observed during the projected treatment
Grade ≧1 Grade ≧2
TJ-14 (n = 43) Placebo (n = 47) p value TJ-14 (n = 43) Placebo (n = 47) p value
Anorexia 20 (46.5 %) 18 (38.3 %) 0.431 2 (4.7 %) 4 (8.5 %) 0.463
Nausea 12 (27.9 %) 18 (38.3 %) 0.296 1 (2.3 %) 3 (6.4 %) 0.351
Vomiting 2 (4.7 %) 2 (4.3 %) 0.927 0 (0.0 %) 0 (0.0 %) 1.000
Diarrhea 9 (20.9 %) 9 (19.1 %) 0.833 1 (2.3 %) 1 (2.1 %) 0.949
Constipation 4 (9.3 %) 8 (17.0 %) 0.282 0 (0.0 %) 0 (0.0 %) 1.000
Peripheral neuropathy 8 (18.6 %) 4 (8.5 %) 0.159 1 (2.3 %) 1 (2.1 %) 0.949
Numbness 2 (4.7 %) 1 (2.1 %) 0.505 0 (0.0 %) 0 (0.0 %) 1.000
Lassitude 3 (7.0 %) 2 (4.3 %) 0.573 0 (0.0 %) 0 (0.0 %) 1.000
Hand-foot syndrome 5 (11.6 %) 4 (8.5 %) 0.622 0 (0.0 %) 1 (2.1 %) 0.336
Skin reaction 2 (4.7 %) 1 (2.1 %) 0.505 1 (2.3 %) 0 (0.0 %) 0.293
Abdominal pain 1 (2.3 %) 0 (0.0 %) 0.293 0 (0.0 %) 0 (0.0 %) 1.000
Abnormal taste 3 (7.0 %) 0 (0.0 %) 0.066 0 (0.0 %) 0 (0.0 %) 1.000
Itchiness 0 (0.0 %) 1 (2.1 %) 0.336 0 (0.0 %) 0 (0.0 %) 1.000
Change in PS 0 (0.0 %) 0 (0.0 %) 1.000 0 (0.0 %) 0 (0.0 %) 1.000
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effect of TJ-14 over placebo in terms of the duration of 
oral mucositis could be a robust evidence for the efficacy 
of TJ-14. Historically, management of oral mucositis in 
cancer patients has been limited to supportive care, includ-
ing pain control, nutritional support, hydration, and wound 
care. Simple nonspecific interventions such as cryotherapy 
and compound mouthwashes that include a topical and 
local anesthetic agent were also shown to have some ben-
efit. Although these interventions may be beneficial, they 
are not directed to the fundamental mechanism changes 
associated with the pathophysiology of oral mucositis. The 
current paradigm for mucosal injury in cancer patients, 
who underwent 5-FU-based chemotherapy, is based on a 
complex cascade of mucosal tissue changes that appear to 
be initiated within hours of exposure to cytotoxic agents 
[29, 30].
Previously, there was some evidence to recommend the 
use of benzydamine mouthwash　or misoprostol mouth-
wash for the prevention of oral mucositis in head and neck 
cancer patients receiving radiation therapy [31, 32]. Benzy-
damine hydrochloride is a nonsteroidal anti-inflammatory 
drug (NSAID), which has been shown to inhibit inflamma-
tory cytokine production, such as TNF-α and IL-1β. Mis-
oprostol is a synthetic analog of prostaglandin E1 (PGE1), 
which has anti-inflammatory properties [33, 34]. Misopros-
tol also protects the mucosa and has been approved for 
reducing the risk of gastric ulcers induced by NSAID use 
[32, 35]. Although positive results were reported for some 
other anti-inflammatory agents in the patients who received 
radiation therapy, no guidelines were able to be developed 
for any other agents due to insufficient and/or conflicting 
evidence for COM.
In conclusion, the present study results did not meet 
the primary endpoint. However, TJ-14 demonstrated a 
significant effect in the treatment of grade ≧2 mucosi-
tis in patients with colorectal cancer compared to the 
placebo. Another extensive randomized placebo-con-
trolled phase III study to reconfirm the effect of TJ-14 is 
warranted.
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